Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

The first release candidate (RC0) of SQL Server 2025 is now available. As we move toward general availability, our focus shifts to delivering enhanced stability, performance, and product improvements ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has seen significant share price volatility in 2025, dropping 27% year-to-date and trading over 55% below its 52-week high of $12. Despite this underperformance ...

The human faculty to generate an infinite set of structured expressions in language, present in most cultures and normal ontogeny, is the most substantial evidence of the human capacity for recursion.

At Microsoft Build 2025, we announced the public preview of SQL Server 2025. Built on a foundation of best-in-class security, performance, and availability, SQL Server 2025 empowers customers to ...